May. 18 at 5:31 PM
$MDXH Annual Financial Guidance & Liquidity Snapshot
FY 2026 Revenue Guidance
Reaffirmed at
$110 million -
$115 million, representing a robust 20% to 26% annual growth rate for the core oncology business.
Liquidity Status
Cash balance stood at
$43.2 million as of March 31, but dropped to approximately
$28.2 million after a mandatory
$15 million deferred milestone payment for ExoDx on April 15.
Market Outlook
While Wall Street analysts have temporarily penalized the stock over the Medicare dispute, the fundamental business emerges leaner, faster-growing, and technologically superior.
